52 results
6-K
EX-99.1
IMRN
Immuron Limited
15 Apr 24
Report of Foreign Private Issuer
8:00am
Steve Lydeamore, CEO Immuron, Dr. Joanne Casey, R&D Manager Immuron, and Dr. Jerry Kanellos, COO Immuron, as they explore the Company’s positive Phase
6-K
EX-99.1
IMRN
Immuron Limited
28 Feb 24
Results for announcement to the market
8:08am
to suppliers and employees
Australian R&D tax incentive refund
Grants received from government and non-government sources
Net cash outflow from operating … and development (R&D): income and expenses directly attributable to the group’s R&D projects performed in Australia and United States.
Hyperimmune products
6-K
EX-99.1
IMRN
Immuron Limited
21 Feb 24
Report of Foreign Private Issuer
8:00am
TRIALS JERRY KANELLOS, PhD Chief Scientific Officer Presented by: JOANNE CASEY, PhD R&D Manager
Certain statements made in this presentation … - relevant enteric pathogens 20
US DOD R&D COLLABORATIVE AGREEMENTS ▪ Immuron history of collaboration with NMRC since 2015 ▪ R&D focused on diarrheal
6-K
EX-99.1
IMRN
Immuron Limited
28 Sep 23
Report of Foreign Private Issuer
8:43am
from contracts with customers
Other Income:
Australian R&D tax incentive refund
MTEC R&D grant
HJF R&D grant
EMDG grant
Other income
Total Other … of $398,391 offset by an over estimation from the prior period of $5,514 (2022: $257,500) to recognize income over the year necessary to match the R&D tax
6-K
EX-99.1
pb7k2nx 8isrun92kibf
30 Aug 23
Preliminary Final Report
6:04am
6-K
EX-99.1
ikt 1s98ubh
24 Jul 23
Immuron CEO, Steven Lydeamore to present at Bioshares
6:04am
6-K
EX-99.1
z4l50z9sadnb12rup5x
21 Nov 22
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
1km gpmiid8adhvs52
16 Nov 22
Immuron completes strategic investment in leading gut health biotech Ateria Health
6:07am
6-K
EX-99.1
cw7dxe2nrkby2zc utg
26 Oct 22
Report of Foreign Private Issuer
6:10am
6-K
EX-99.1
6b7f 4n88gh
13 Oct 22
Immuron strategic investment in leading gut health biotech Ateria Health
6:10am
6-K
EX-99.2
yue54
31 Aug 22
Preliminary Final Report
7:50am
6-K
EX-99.1
ranz2i3xn9js1k88ah28
31 Aug 22
Preliminary Final Report
7:50am
6-K
EX-99.1
k088orbd yjrv4ng
25 Feb 22
Results for announcement to the market
7:37am
6-K
EX-99.1
nv8xoy2
18 Jan 22
Immuron Receives AUD $306,154 R&D Tax Concession Refund
6:05am
6-K
48p yfw9lrhd6r
18 Jan 22
Immuron Receives AUD $306,154 R&D Tax Concession Refund
6:05am
6-K
EX-99.1
nqsc1yy wd
8 Oct 21
Report of Foreign Private Issuer
6:05am
6-K
EX-99.1
f9k 2iw98a
30 Sep 21
Annual report - 30 June 2021
11:42am